Junshi, Coherus expand immuno-oncology collaboration to cover TIGIT

Coherus exercised an option to Junshi’s anti-TIGIT mAb JS006, expanding an immuno-oncology partnership initiated last year as the original therapy covered by the agreement nears the U.S. market.

Coherus BioSciences Inc. (NASDAQ:CHRS) will pay $35 million up front for U.S. and Canadian rights to JS006, which is in a Chinese Phase I study as monotherapy and in combination with Junshi’s PD-1 inhibitor Tuoyi toripalimab. The deal includes $255 million in milestones and an 18% royalty on net sales...